Trademark: 97715574
Word
BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV
Status Date
Monday, March 4, 2024
Filing Date
Tuesday, December 13, 2022
Published for Opposition
Tuesday, July 11, 2023
5 pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncological diseases, the foregoing featuring monoclonal antibodies
The mark consists of the text "BRIUMVI" in black above the text "UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV" in dark grey with the "B" in "BRIUMVI" partially surrounded by a light blue sphere edged in gold.
The color(s) black, dark grey, light blue and gold is/are claimed as a feature of the mark.
The wording BRIUMVI has no meaning in a foreign language.
"150 MG/6ML INJECTION FOR IV"
Mar 5, 2024
Notice Of Approval Of Extension Request E-Mailed
Mar 4, 2024
Sou Extension 1 Granted
Mar 4, 2024
Sou Extension 1 Filed
Mar 4, 2024
Sou Teas Extension Received
Sep 5, 2023
Noa E-Mailed - Sou Required From Applicant
Jul 11, 2023
Official Gazette Publication Confirmation E-Mailed
Jul 11, 2023
Published For Opposition
Jun 21, 2023
Notification Of Notice Of Publication E-Mailed
Jun 7, 2023
Approved For Pub - Principal Register
Jun 6, 2023
Teas/Email Correspondence Entered
Jun 6, 2023
Correspondence Received In Law Office
Jun 6, 2023
Teas Response To Office Action Received
Mar 9, 2023
Notification Of Non-Final Action E-Mailed
Mar 9, 2023
Non-Final Action E-Mailed
Mar 9, 2023
Non-Final Action Written
Mar 8, 2023
Assigned To Examiner
Jan 11, 2023
Notice Of Design Search Code E-Mailed
Jan 10, 2023
New Application Office Supplied Data Entered
Dec 16, 2022
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
